Drug Information and Pharmacotherapy

DI-029

ANALYSIS OF THE MODIFICATIONS IN ANTIRETROVIRAL TREATMENT

DI-028

REASONS FOR CHANGING TREATMENT TO ORAL AGENTS IN MULTIPLE SCLEROSIS

DI-025

INTRAVENOUS IMMUNOGLOBULIN INDUCED AGRANULOCYTOSIS

DI-024

 USE OF A NALOXONE TRIGGER TOOL AND MULTIDISCIPLINARY CAUSALITY ASSESSMENT TO IDENTIFY AND CONFIRM OPIOID RELATED ADVERSE DRUG EVENTS 

DI-023

UTILISATION STUDY OF ORAL ANTICOAGULANTS (2008-2015) AND BLEEDINGS DUE TO ANTICOAGULANT TREATMENT (2012 – 2015)

DI-022

USE AND CLINICAL EXPERIENCE OF DOLUTEGRAVIR/ABACAVIR/LAMIVUDINA IN A TERTIARY HOSPITAL

DI-020

TOXIC EPIDERMAL NECROLYSIS RESULTING IN A FATAL OUTCOME CAUSED BY USE OF LAMOTRIGINE

DI-019

EFECTIVENESS AND SAFETY OF NEW ANTIVIRALS AGENTS IN HIV PATIENTS WITH CHRONIC HEPATITIS C

DI-016

USE OF ARILOCUMAB AND EVOLOCUMAB: LIPID LOWERING THERAPIES

DI-015

SAFETY OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING–REMITTING MULTIPLE SCLEROSIS: A RETROSPECTIVE STUDY

DI-014

CONTINUING USE OF OUTPATIENT PRESCRIPTION DRUGS IN PATIENTS HOSPITALISED ON A CARDIOLOGY WARD DOES NOT IMPROVE MEDICATION KNOWLEDGE

DI-013

COST PER RESPONDER TO USTEKINUMAB BASED ON THE FIRSTLINE ANTI-TNFαTREATMENT IN MODERATE-SEVERE PSORIASIS

DI-011

ANALYSIS OF OFF-LABEL USE IN BIOLOGICAL THERAPIES

DI-010

A SYSTEMATIC LITERATURE REVIEW OF ANTIMICROBIAL STABILITY DATA IN ELASTOMERIC DEVICES

DI-007

SIROLIMUS FOR THE TREATMENT OF COMPLICATED VASCULAR ANOMALIES IN CHILDREN

Pages